Evidence map›Paper›PMID 33513963›Full record

ArticleMolecules (Basel, Switzerland)2021

New Substituted 5-Benzylideno-2-Adamantylthiazol[3,2-b][1,2,4]Triazol-6(5

Christophe Tratrat, Michelyne Haroun, Aliki Paparisva, Charalmpos Kamoutsis, Anthi Petrou, Antonis Gavalas, Phaedra Eleftheriou, Athina Geronikaki, Katharigatta N Venugopala, Hafedh Kochkar and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Christophe TratratDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
Michelyne HarounDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
Aliki PaparisvaSchool of Pharmacy, University of Thessaloniki, 54124 Thessaloniki, Greece.
Charalmpos KamoutsisSchool of Pharmacy, University of Patras, 26504 Patra, Greece.
Anthi PetrouSchool of Pharmacy, University of Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0001-8587-2710
Antonis GavalasSchool of Pharmacy, University of Thessaloniki, 54124 Thessaloniki, Greece.
Phaedra EleftheriouDepartment of Biomedical Sciences, School of Health Sciences, International Hellenic University, 57400 Thessaloniki, Greece.
Athina GeronikakiSchool of Pharmacy, University of Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0001-9894-7777
Katharigatta N VenugopalaDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
Hafedh KochkarDepartment of Chemistry, College of Science, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.
Anroop B NairDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.ORCID 0000-0003-2850-8669
Aristotle University of Thessaloniki · GRKing Faisal University · SADurban University of Technology · ZAImam Abdulrahman Bin Faisal University · SAInternational Hellenic University · GRUniversity of Patras · GR

Funding

Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia 186225
6 · The paper itself

Abstract

backgroundInflammation is a complex response to noxious stimuli promoted by the release of chemical mediators from the damaged cells. Metabolic products of arachidonic acid, produced by the action of cyclooxygenase and lipoxygenase, play important roles in this process. Several non-steroidal anti-inflammatory drugs act as cyclooxygenase inhibitors. However, almost all of them have undesired side effects.

methodsPrediction of the anti-inflammatory action of the compounds was performed using PASS Program. The anti-inflammatory activity was evaluated by the carrageenan paw edema test. COX and LOX inhibitory actions were tested using ovine COX-1, human recombinant COX-2 and soybean LOX-1, respectively. Docking analysis was performed using Autodock.

resultsAll designed derivatives had good prediction results according to PASS and were synthesized and experimentally evaluated. The compounds exhibited in vivo anti-inflammatory action with eleven being equal or better than indomethacin. Although, some of them had no or low inhibitory effect on COX-1/2 or LOX, certain compounds exhibited COX-1 inhibition much higher than naproxen and COX-2 inhibition, well explained by Docking analysis.

conclusionsA number of compounds with good anti-inflammatory action were obtained. Although, some exhibited remarkable COX inhibitory action this activity did not follow the anti-inflammatory results, indicating the implication of other mechanisms.

Indexed as

AnimalsAnti-Inflammatory AgentsArachidonic AcidCarrageenanCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsEdemaFemaleHumansInflammationLipoxygenaseLipoxygenase InhibitorsMaleMiceAnti-Inflammatory AgentsArachidonic AcidCarrageenanCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsLipoxygenaseLipoxygenase InhibitorsNaproxenTriazolesanti-inflammatorycarrageenanCOXdockingLOXNDGAthiazoletriazole

Identifiers

PMID33513963
PMCPMC7866232
OpenAlexW3125517420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.